Visus Therapeutics Announces Positive Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL PF™ for the Treatment of Presbyopia. For full details click here.
CLICK TO CLOSE
Click to Open
illuminating
OUR MISSION
Visus Therapeutics™ is a clinical-stage pharmaceutical company lighting the way to dramatically improve patient lives through the development of differentiated, best-in-class ophthalmic therapies.
And we're just getting started...
DISCOVER OUR PIPELINE TODAYDiscover our pipeline today.
With officies in Seattle and Orange County, Visus is home to our lead clinical candidate, BRIMOCHOL™ (carbachol + brimonidine tartrate), an eye drop being evaluated to correct the loss of near vision associated with presbyopia.
